Pembrolizumab (Keytruda)

Pembrolizumab, better known by its brand name Keytruda, is a type of cancer immunotherapy. Instead of attacking cancer cells directly, it helps the immune system recognize and fight them more effectively

What Keytruda Does?

Your immune system has “brakes” that stop it from attacking healthy cells. Cancer cells often exploit these brakes to hide. Keytruda works by releasing one of those brakes, specifically a protein called PD‑1, so immune cells can finally see and attack the cancer.

What It’s Used For?

Keytruda is widely used to treat several cancers, including:

• Non‑small cell lung cancer (NSCLC)

• Melanoma

• Head and neck cancers

• Some colorectal cancers

• Many others, depending on specific biomarkers

It’s usually given through an IV infusion every few weeks.

PD‑L1 and PD‑L2 are like “don’t attack me” signals that tumors use to shut down T cells. When these signals connect with the PD‑1 receptor on T cells, the immune cell essentially receives a stop order, even if the target is a dangerous cancer cell.

How PD‑L1 and PD‑L2 Stop T Cells From Killing Tumors

1. T cells need permission to attack

T cells are powerful immune soldiers. To prevent them from harming healthy tissues, the body built a safety system:

• T cells have a receptor called PD‑1.

• When PD‑1 is activated, the T cell slows down or shuts off.

This is normally good—it prevents autoimmunity.

2. Tumors hijack this safety system

Many cancer cells express PD‑L1 or PD‑L2, the molecules that bind to PD‑1.
When PD‑L1/PD‑L2 on the tumor binds to PD‑1 on the T cell, it sends a message:

“Stand down. Do not attack.”

This causes:

• T cells to become exhausted

• T cells to stop releasing toxic molecules

• T cells to stop multiplying

• The immune response to collapse around the tumor

The tumor survives by pretending to be harmless.

3. The PD‑1/PD‑L1 interaction is like hitting the brakes

You can think of it like this:

• PD‑1 = the brake pedal on the T cell

• PD‑L1/PD‑L2 = the foot pressing the brake

When the brake is pressed, the T cell cannot chase or kill cancer cells.

4. Why drugs like Keytruda help

Pembrolizumab (Keytruda) is a PD‑1 blocker.
It sits on the PD‑1 receptor and prevents PD‑L1/PD‑L2 from binding.

This is like removing the foot from the brake pedal, allowing the T cell to:

• Wake up

• Recognize the tumor

• Attack and kill cancer cells again